Real-world evidence of the use of glucocorticoids for severe COVID-19.

Introduction: Currently, only glucocorticoids have proved to impact adverse outcomes in COVID-19. However, their risk/benefit balance remains inconclusive and populations' characteristics should be considered.

Objective: The objective was to evaluate the real-life use of glucocorticoids in patients with severe COVID-19 hospitalized in a third-level referral center and to determine the type, accumulated doses, and the in-hospital outcomes related with their use.

[Adult-onset Still's disease and the neutrophil-lymphocyte index in the Mexican population. A case series report].

Background: In Mexico, adult-onset Still's disease (AOSD) is one of the causes of fever of unknown origin (FUO). The aim of this study is to describe a series of AOSD cases from a FUO cohort in order to know the clinical and biochemical characteristics of the cases, as well as to describe the neutrophil-lymphocyte index (NLI), which is a clinical marker of inflammation in autoimmune diseases.

Case Report: An observational study of 24 cases with AOSD; 72 % of them were women, the median age was 43 years (IQR 37.